Search

everythinglearnresearchcommunity

for

Search:↓

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

A rash from semaglutide may be due to propylene glycol, not the drug itself.

Baricitinib is the most effective treatment for alopecia areata.

Controlling Tslp can improve health in AEC syndrome patients.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Individualized treatments may help manage Dercum's disease symptoms.

The research found that a protein called caveolin-1 is reduced in psoriasis, but reintroducing it can help alleviate some psoriasis symptoms.

Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.

Apremilast did not work for treating severe alopecia areata.

A patient lost all their hair while on rheumatoid arthritis medication.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.